Φορτώνει......
Eculizumab and Recurrent C3 Glomerulonephritis
BACKGROUND AND OBJECTIVES: Hyperactivity of the alternative complement pathway is the principle defect in the C3 glomerulopathies (C3G). Eculizumab, a monoclonal antibody that binds to C5 to prevent formation of the membrane attack complex, has been shown to be beneficial in some patients with this...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Pediatr Nephrol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2013
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4428658/ https://ncbi.nlm.nih.gov/pubmed/23689905 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00467-013-2503-y |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|